Cargando…
Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells
BACKGROUND: Bone morphogenetic proteins (BMP) are evolutionarily conserved morphogens that are reactivated in lung carcinomas. In lung cancer cells, BMP signaling suppresses AMP activated kinase (AMPK) by inhibiting LKB1. AMPK is activated by mitochondrial stress that inhibits ATP production, which...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238106/ https://www.ncbi.nlm.nih.gov/pubmed/35761398 http://dx.doi.org/10.1186/s12964-022-00905-4 |
_version_ | 1784736955828797440 |
---|---|
author | Mondal, Arindam Roberge, Jacques Gilleran, John Peng, Youyi Jia, Dongxuan Akel, Moumen Patel, Yash Zoltowski, Harrison Doraiswamy, Anupama Langenfeld, John |
author_facet | Mondal, Arindam Roberge, Jacques Gilleran, John Peng, Youyi Jia, Dongxuan Akel, Moumen Patel, Yash Zoltowski, Harrison Doraiswamy, Anupama Langenfeld, John |
author_sort | Mondal, Arindam |
collection | PubMed |
description | BACKGROUND: Bone morphogenetic proteins (BMP) are evolutionarily conserved morphogens that are reactivated in lung carcinomas. In lung cancer cells, BMP signaling suppresses AMP activated kinase (AMPK) by inhibiting LKB1. AMPK is activated by mitochondrial stress that inhibits ATP production, which is enhanced 100-fold when phosphorylated by LKB1. Activated AMPK can promote survival of cancer cells but its “hyperactivation” induces cell death. The studies here reveal novel cell death mechanisms induced by BMP inhibitors, together with agents targeting the mitochondria, which involves the “hyperactivation” of AMPK. METHODS: This study examines the synergistic effects of two BMP inhibitors together with mitochondrial targeting agents phenformin and Ym155, on cell death of lung cancer cells expressing LKB1 (H1299), LKB1 null (A549), and A549 cells transfected with LKB1 (A549-LKB1). Cell death mechanisms evaluated were the activation of caspases and the nuclear localization of apoptosis inducing factor (AIF). A769662 was used to allosterically activate AMPK. Knockdown of BMPR2 and LKB1 using siRNA was used to examine their effects on nuclear localization of AMPK. Validation studies were performed on five passage zero primary NSCLC. RESULTS: Both BMP inhibitors synergistically suppressed growth when combined with Ym155 or phenformin in cells expressing LKB1. The combination of BMP inhibitors with mitochondrial targeting agents enhanced the activation of AMPK in lung cancer cells expressing LKB1. Allosteric activation of AMPK with A769662 induced cell death in both H1299 and A549 cells. Cell death induced by the combination of BMP inhibitors and mitochondrial-targeting agents did not activate caspases. The combination of drugs induced nuclear localization of AIF in cells expressing LKB1, which was attenuated by knockdown of LKB1. Knockdown of BMPR2 together with Ym155 increased nuclear localization of AIF. Combination therapy also enhanced cell death and AIF nuclear localization in primary NSCLC. CONCLUSIONS: These studies demonstrate that inhibition of BMP signaling together with mitochondrial targeting agents induce AIF caspase-independent cell death, which involves the “hyperactivation” of AMPK. AIF caspase-independent cell death is an evolutionarily conserved cell death pathway that is infrequently studied in cancer. These studies provide novel insight into mechanisms inducing AIF caspase-independent cell death in cancer cells using BMP inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00905-4. |
format | Online Article Text |
id | pubmed-9238106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92381062022-06-29 Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells Mondal, Arindam Roberge, Jacques Gilleran, John Peng, Youyi Jia, Dongxuan Akel, Moumen Patel, Yash Zoltowski, Harrison Doraiswamy, Anupama Langenfeld, John Cell Commun Signal Research BACKGROUND: Bone morphogenetic proteins (BMP) are evolutionarily conserved morphogens that are reactivated in lung carcinomas. In lung cancer cells, BMP signaling suppresses AMP activated kinase (AMPK) by inhibiting LKB1. AMPK is activated by mitochondrial stress that inhibits ATP production, which is enhanced 100-fold when phosphorylated by LKB1. Activated AMPK can promote survival of cancer cells but its “hyperactivation” induces cell death. The studies here reveal novel cell death mechanisms induced by BMP inhibitors, together with agents targeting the mitochondria, which involves the “hyperactivation” of AMPK. METHODS: This study examines the synergistic effects of two BMP inhibitors together with mitochondrial targeting agents phenformin and Ym155, on cell death of lung cancer cells expressing LKB1 (H1299), LKB1 null (A549), and A549 cells transfected with LKB1 (A549-LKB1). Cell death mechanisms evaluated were the activation of caspases and the nuclear localization of apoptosis inducing factor (AIF). A769662 was used to allosterically activate AMPK. Knockdown of BMPR2 and LKB1 using siRNA was used to examine their effects on nuclear localization of AMPK. Validation studies were performed on five passage zero primary NSCLC. RESULTS: Both BMP inhibitors synergistically suppressed growth when combined with Ym155 or phenformin in cells expressing LKB1. The combination of BMP inhibitors with mitochondrial targeting agents enhanced the activation of AMPK in lung cancer cells expressing LKB1. Allosteric activation of AMPK with A769662 induced cell death in both H1299 and A549 cells. Cell death induced by the combination of BMP inhibitors and mitochondrial-targeting agents did not activate caspases. The combination of drugs induced nuclear localization of AIF in cells expressing LKB1, which was attenuated by knockdown of LKB1. Knockdown of BMPR2 together with Ym155 increased nuclear localization of AIF. Combination therapy also enhanced cell death and AIF nuclear localization in primary NSCLC. CONCLUSIONS: These studies demonstrate that inhibition of BMP signaling together with mitochondrial targeting agents induce AIF caspase-independent cell death, which involves the “hyperactivation” of AMPK. AIF caspase-independent cell death is an evolutionarily conserved cell death pathway that is infrequently studied in cancer. These studies provide novel insight into mechanisms inducing AIF caspase-independent cell death in cancer cells using BMP inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00905-4. BioMed Central 2022-06-27 /pmc/articles/PMC9238106/ /pubmed/35761398 http://dx.doi.org/10.1186/s12964-022-00905-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mondal, Arindam Roberge, Jacques Gilleran, John Peng, Youyi Jia, Dongxuan Akel, Moumen Patel, Yash Zoltowski, Harrison Doraiswamy, Anupama Langenfeld, John Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells |
title | Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells |
title_full | Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells |
title_fullStr | Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells |
title_full_unstemmed | Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells |
title_short | Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells |
title_sort | bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (aif) caspase-independent cell death in lung cancer cells |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238106/ https://www.ncbi.nlm.nih.gov/pubmed/35761398 http://dx.doi.org/10.1186/s12964-022-00905-4 |
work_keys_str_mv | AT mondalarindam bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells AT robergejacques bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells AT gilleranjohn bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells AT pengyouyi bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells AT jiadongxuan bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells AT akelmoumen bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells AT patelyash bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells AT zoltowskiharrison bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells AT doraiswamyanupama bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells AT langenfeldjohn bonemorphogeneticproteininhibitorsandmitochondriatargetingagentssynergisticallyinduceapoptosisinducingfactoraifcaspaseindependentcelldeathinlungcancercells |